Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rothschedl E, Nachtnebel A. Bevacizumab (AvastinĀ®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology No. 56. 2016 Authors' objectives To evaluate the efficacy and safety of the addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer. Authors' conclusions The addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer showed no survival benefit in the overall study population. However, high-risk patients with a poor prognosis achieved a benefit in OS, although it has to be considered that the increase is based on data of the ICON7 trial using an unlicensed dose of bevacizumab. Furthermore, the improvements in PFS are not statistically significant. Hence, high additional costs and increased AEs stand in contrast to modest efficacy improvements. However, the impact of any prolongation of the patient's life might be relevant, even if the addition of bevacizumab is not associated with an improved quality of life. Since the ICON7 trial was conducted with an unlicensed dose of bevacizumab, it is difficult to assess the applicability of the results and, not least, their impact on the treatment costs. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Bevacizumab; Female; Humans; Ovarian Neoplasms Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32016000987 Date abstract record published 14/09/2016 |